In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study

Diagn Microbiol Infect Dis. 2011 Jun;70(2):270-3. doi: 10.1016/j.diagmicrobio.2010.12.018.

Abstract

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and methicillin resistant Staphylococcus aureus (MRSA) are important nosocomial pathogens. This study reports the in vitro activity of tigecycline against 573 and 482 ESBL-producing Enterobacteriaceae and MRSA isolates, respectively. More than 94% of all tested isolates were susceptible to tigecycline; MIC(90) found was 0.25 to 2 mg/L for ESBL-producing Enterobacteriaceae and was 0.125 mg/L for MRSA. Tigecycline demonstrated excellent in vitro activity against a wide spectrum of nosocomial pathogens.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology*
  • Cross Infection / microbiology
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / microbiology*
  • Female
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / enzymology
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification
  • Mexico
  • Microbial Sensitivity Tests
  • Middle Aged
  • Minocycline / analogs & derivatives*
  • Minocycline / pharmacology
  • Staphylococcal Infections / microbiology*
  • Tigecycline
  • Young Adult
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • Tigecycline
  • beta-Lactamases
  • Minocycline